STAT3 and hepatocellular carcinoma: Resistance mechanisms include the activation of EGFR and stimulation of the EGFR–STAT3–ABCB1 axis, suggesting that EGFR inhibitors may be effective in addressing acquired lenvatinib resistance in HCC [53].